NRx Pharmaceuticals Files Citizen's Petition to Remove Toxic Ketamine Preservative

Citizen's Petition to Remove Benzethonium Chloride

• 💡 NRx Pharmaceuticals has filed a citizen's petition with the FDA to remove benzethonium chloride from ketamine products.
• 🎯 This preservative, a type of quaternary amine, was commonly added to drugs in the 1970s to prevent bacterial growth in multi-use vials.
• 🔑 The petition argues that this preservative is no longer necessary due to changes in medical practice (single-use vials) and has potential toxicity.

Toxicity of Preservatives

• 🔬 Benzethonium chloride has been linked to toxicity, particularly causing dry eye symptoms by damaging epithelial cells, similar to other preservatives found in eye drops.
• ⚠️ The FDA has recently deemed benzethonium chloride unsafe for use in hand cleansers and topical antiseptics.
• 🧠 The FDA has not previously addressed the toxicity of this preservative in injectable products because no new applications were submitted until recently.

Potential Market Impact for NRx

• 🚀 If the FDA agrees with the petition, NRx could become the only FDA-approved supplier of preservative-free ketamine.
• 💰 This could reshape a market estimated at $750 million annually, offering safer options for patients.
• 📈 NRx has filed an abbreviated new drug application for preservative-free ketamine and holds a patent for its formulation, challenging prior art that suggested the preservative was necessary.

FDA Response and Timeline

• ⏳ The FDA is legally required to respond to the petition within six months.
• 🗣️ However, given the current Secretary of Health and Human Services' attention to toxic preservatives, a response may come sooner.